저자들은 1986년 1월부터 1987년 4월까지 조기진통의 진단하에 전주예수병원 산부인과에 입원한 산모에서 Ritodrine투여를 시행하고 분만시까지 추적된 25명의 산모를 대상으로 연구 분석하여 다음과 같은 결과를 얻었다. 1. 산모들의 연령 임신주수 임신력에서는 유의한 차이가 없었으며, 자궁경부개대 및 자궁경부 소실상태나 tocolysis score치는 치료성적과 유의한 관계를 보였다. 2. 1주일이상의 분만지연 혹은 임신37주이후의 분만을 치료성공의 기준으로 했을때 치료성공률은 32%이었으며, 평균 분만지연일은 25일이었다. 3. Ritodrine투여시 임산부의 혈압과 태아의 맥박수는 유의한 차이를 보이지 않았으나 임산부의 맥박수는 유의하게 증가하였다. 4. 치료 실패요인은 심한 모체 빈맥 감염 질출혈과 무반응 예로 구분되는데 무반응 예가 전체 실패 예의 76%로서 가장 많았다. 5. Ritochine투여로 인한 신생아의 Apgar score의 저하는 없었다.

Preterm delivery accounts for 70 % of the perinatal mortality and morbidity and is therefore the principal target of obstetric dept. The beta-adrenergic agonist such as ritodrine hydrochloride (Yutopar) has demonstrated a significant prolongation in the duration of pregnancy and a decrease in immediate neonatal morbidity through several placebo-controlled studies in recent years. This study was conducted for the evaluation of the effectiveness of ritodrine hydrochloride on 25 patients selected in 104 patients admitted with preterm labor from January, 1986 to April, 1987. The results of this study were as follows: 1. There was no significant difference in clinical characteristics such as maternal age, gestational weeks, gravity and parity. But the high tocolysis score, progressed cervical dilatation and good cervical effacement were noted in the failure group. 2. The total success rate of tocolysis was 32 % and the mean time gained by ritodrine was 25 days. 3. There was no significant difference in maternal blood pressure and fetal heart rate during ritodrine infusion but the maternal tachycardia was noted. 4. The causes of treatment failure were severe maternal tachycardia, infection, vaginal bleeding and unresponsiveness. The unresponsiveness cases were 76 % of the total failure group. 5. The mean Apgar score of neonate born before 34 weeks of gestation was 4.8 (1-min)/7.3(5-min) and 7.2(1-min)/9.1(5-min) after 34 weeks gestation. There was no decrease in Apgar score from ritodrine infusion.